Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NNVC NYSEAMERICAN:NTN OTCMKTS:PVOTF NYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNNVCNanoViricides$1.60+9.6%$1.46$0.94▼$2.55$25.72M0.88236,588 shs557,051 shsNTNNTN Buzztime$1.92-2.0%$1.11$0.94▼$7.76$5.72M0.721.63 million shs48,990 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNNVCNanoViricides+9.59%+14.29%+10.34%+20.30%-21.57%NTNNTN Buzztime-2.04%0.00%-16.16%+858.56%+0.03%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNNVCNanoViricides0.2881 of 5 stars0.03.00.00.02.60.00.0NTNNTN BuzztimeN/AN/AN/AN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNNVCNanoViricides 0.00N/AN/AN/ANTNNTN Buzztime 0.00N/AN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ANTNNTN Buzztime$19.81M0.29$0.44 per share4.38$1.76 per share1.09PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ANTNNTN Buzztime-$2.05MN/AN/A∞N/A-61.42%-162.54%-49.94%N/APVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNNVCNanoViricidesN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNNVCNanoViricidesN/A3.442.47NTNNTN Buzztime3.300.950.95PVOTFBetterLife PharmaN/A3.623.62SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNNVCNanoViricides10.30%NTNNTN Buzztime6.31%PVOTFBetterLife PharmaN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipNNVCNanoViricides4.60%NTNNTN Buzztime24.20%PVOTFBetterLife Pharma34.77%SYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNNVCNanoViricides2016.07 million14.92 millionOptionableNTNNTN Buzztime192.98 millionN/ANot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableNTN, NNVC, PVOTF, and SYN HeadlinesRecent News About These CompaniesSynthetic Darwin and Star26 Capital Partner to Advance Defense AI5 hours ago | tmcnet.comThe Hidden Downside Of Synthetic Stone Countertops5 hours ago | msn.comPakenham Synthetic Monday tips: Laying a $2.30FJuly 15 at 12:38 PM | punters.com.auPBallarat Synthetic Tuesday tips: $11 value betJuly 15 at 12:38 PM | punters.com.auPMost Major Ice Cream Brands Will Remove Synthetic Dyes by 2028July 15 at 12:38 PM | usnews.comSarcoidosis: Infliximab Has Some Effect, Other Third-Line Therapies Show PromiseJuly 11, 2025 | pulmonologyadvisor.comPSynthetic Dyes Present in 19% of US Food ProductsJuly 9, 2025 | empr.comEBallarat Synthetic preview and tips: $11 value betJuly 9, 2025 | punters.com.auPSynthetic Dyes Present in 19 Percent of U.S. Food ProductsJuly 4, 2025 | msn.comFlexiteek Expands Synthetic Decking Line with New Tritone FinishJuly 3, 2025 | msn.comControversial ‘Synthetic Human Genome Project’ Spurs Debate Over Ethics of Building Human DNA from ScratchJuly 2, 2025 | thedebrief.orgTOn The Punt: Gilbert Gardiner's tips for Ballarat Synthetic on TuesdayJuly 2, 2025 | punters.com.auPSynthetic data, real results: Rewiring industrial inspection to work with AIJuly 1, 2025 | imveurope.comIUK launches bold Synthetic Human Genome Project: Can human DNA be built from scratch?June 27, 2025 | indiatvnews.comIAstroTurf Secures Historic Partnership as Official Synthetic Turf of Major League BaseballJune 27, 2025 | sfexaminer.comSSynthetic DNA research could lead to the creation of artificial life, Irish professor saysJune 27, 2025 | independent.ieIWhich mesh is best? Outcomes for abdominal ventral hernia repair patients projected by new research modelJune 25, 2025 | medicaldialogues.inMEULAR Updates Recommendations for Managing Rheumatoid ArthritisJune 20, 2025 | medscape.comMBenefits of early biologic treatment in psoriatic arthritis examined in studiesJune 12, 2025 | medicalxpress.comMWhich mesh is best? New research model projects outcomes for abdominal ventral hernia repair patientsJune 4, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTN, NNVC, PVOTF, and SYN Company DescriptionsNanoViricides NYSE:NNVC$1.60 +0.14 (+9.59%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.62 +0.02 (+1.56%) As of 07/16/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.NTN Buzztime NYSEAMERICAN:NTN$1.92 -0.04 (-2.04%) As of 07/15/2025NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
